Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Canada: These 96 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Canada: These 96 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AMITIZA (lubiprostone) generic drug versions launch?
Generic name: lubiprostone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,637,274
Patent Title: FORMULATION DE CAPSULE GELATINEUSE MOLLE (SOFT-GELATIN CAPSULE FORMULATION)
This drug has forty-nine patent family members in nineteen countries. There has been litigation on patents covering AMITIZA
See drug price trends for AMITIZA.
The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lubiprostone profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,602,042
Patent Title: TROUSSE ET COMPOSITION D'IMIDAZOLE PRESENTANT UNE BIODISPONIBILITE ACCRUE (KIT AND COMPOSITION OF IMIDAZOLE WITH ENHANCED BIOAVAILABILITY)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can OTREXUP (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: Canada Patent 2,595,730
Patent Title: INJECTEUR A SERINGUE PREREMPLIE ASSISTE D'UNE AIGUILLE (PREFILLED NEEDLE ASSISTED JET INJECTOR)
This drug has thirty-nine patent family members in fourteen countries. There has been litigation on patents covering OTREXUP
See drug price trends for OTREXUP.
The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can LEXISCAN (regadenoson) generic drug versions launch?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 03, 2026
Generic Entry Controlled by: Canada Patent 2,640,089
Patent Title: PROCEDE DE PREPARATION D'UN AGONISTE DE RECEPTEUR A2A-ADENOSINE ET SES POLYMORPHES (PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS)
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Eighteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can LEXISCAN (regadenoson) generic drug versions launch?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 03, 2026
Generic Entry Controlled by: Canada Patent 2,787,759
Patent Title: PROCEDE DE PREPARATION D'UN AGONISTE DE RECEPTEUR A2A-ADENOSINE ET SES POLYMORPHES (PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS)
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Eighteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 06, 2026
Generic Entry Controlled by: Canada Patent 2,597,016
Patent Title: SEL DE MONOHYDROCHLORURE DE 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE (MONOHYDROCHLORIDE SALT OF 1- [3- [3- (4-CHLOROPHENYL) PROPOXY] PROPYL] -PIPERIDINE)
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can RAPIVAB (peramivir) generic drug versions launch?
Generic name: peramivir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: Canada Patent 2,642,260
Patent Title: TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS)
RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.
This drug has forty-three patent family members in fourteen countries.
See drug price trends for RAPIVAB.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.
When can RAPIVAB (peramivir) generic drug versions launch?
Generic name: peramivir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: Canada Patent 2,649,090
Patent Title: TRAITEMENTS ANTIVIRAUX INTRAMUSCULAIRES (INTRAMUSCULAR ANTIVIRAL TREATMENTS)
RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.
This drug has forty-three patent family members in fourteen countries.
See drug price trends for RAPIVAB.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.
When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?
Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,597,889
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.
This drug has one hundred and six patent family members in twenty-nine countries.
See drug price trends for IZERVAY.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.
When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?
Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,897,900
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.
This drug has one hundred and six patent family members in twenty-nine countries.
See drug price trends for IZERVAY.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.
When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?
Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 2,992,874
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.
This drug has one hundred and six patent family members in twenty-nine countries.
See drug price trends for IZERVAY.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.
When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?
Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2026
Generic Entry Controlled by: Canada Patent 3,124,030
Patent Title: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.
This drug has one hundred and six patent family members in twenty-nine countries.
See drug price trends for IZERVAY.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2026
Generic Entry Controlled by: Canada Patent 2,597,982
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2026
Generic Entry Controlled by: Canada Patent 2,597,982
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 22, 2026
Generic Entry Controlled by: Canada Patent 2,601,955
Patent Title: COMPOSITION PHARMACEUTIQUE COMPRENANT UNE DIPHENYLUREE SUBSTITUEE PAR UN OMEGA-CARBOXYARYLE POUR LE TRAITEMENT DU CANCER (PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA- CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER)
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can HYLENEX RECOMBINANT (hyaluronidase recombinant human) generic drug versions launch?
Generic name: hyaluronidase recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2026
Generic Entry Controlled by: Canada Patent 2,598,823
Patent Title: GLYCOSAMINOGLYCANASES SOLUBLES ET PROCEDES DE PREPARATION ETD'UTILISATION DE GLYCOSAMINOGLYCANASES SOLUBLES (SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES)
HYLENEX RECOMBINANT is a drug marketed by
This drug has eighty-nine patent family members in thirty-nine countries.
The generic ingredient in HYLENEX RECOMBINANT is hyaluronidase recombinant human. There are six drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the hyaluronidase recombinant human profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 24, 2026
Generic Entry Controlled by: Canada Patent 2,537,400
Patent Title: FORME CRISTALLINE Y DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT (Y CRYSTALLINE FORM OF IVABRADINE CHLORHYDRATE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOUNDS CONTAINING IT)
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 24, 2026
Generic Entry Controlled by: Canada Patent 2,537,414
Patent Title: FORME CRISTALLINE B DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT (B CRYSTALLINE FORM OF IVABRADINE CHLORHYDRATE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOUNDS CONTAINING IT)
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can XIFAXAN (rifaximin) generic drug versions launch?
Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2026
Generic Entry Controlled by: Canada Patent 2,594,789
Patent Title: NOUVELLES FORMES POLYMORPHES DE RIFAXIMINE, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION EN MEDECINE (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering XIFAXAN
See drug price trends for XIFAXAN.
The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2026
Generic Entry Controlled by: Canada Patent 2,644,467
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can ACTOPLUS MET XR (metformin hydrochloride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 13, 2026
Generic Entry Controlled by: Canada Patent 2,601,501
Patent Title: NOUVELLE FORMULATION PHARMACEUTIQUE CONTENANT UN BIGUANIDE ET UN DERIVE DE THIAZOLIDINEDIONE (NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE)
This drug has seventy-two patent family members in twenty-five countries. There has been litigation on patents covering ACTOPLUS MET XR
See drug price trends for ACTOPLUS MET XR.
The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2026
Generic Entry Controlled by: Canada Patent 2,600,468
Patent Title: COMPOSITIONS STABILISEES D'AGENTS D'ALKYLATION VOLATILS ET METHODES D'UTILISATION DE CES COMPOSITIONS (STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF)
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2026
Generic Entry Controlled by: Canada Patent 2,645,855
Patent Title: FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2026
Generic Entry Controlled by: Canada Patent 2,601,784
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
This drug has two hundred and thirty-eight patent family members in thirty-three countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2026
Generic Entry Controlled by: Canada Patent 2,601,784
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
This drug has one hundred and eighty-seven patent family members in thirty-three countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can REZUROCK (belumosudil mesylate) generic drug versions launch?
Generic name: belumosudil mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 27, 2026
Generic Entry Controlled by: Canada Patent 2,602,254
Patent Title: COMPOSES PHARMACOCINETIQUEMENT AMELIORES (PHARMACOKINETICALLY IMPROVED COMPOUNDS)
REZUROCK is a drug marketed by Kadmon Pharms Llc. There are five patents protecting this drug.
This drug has fifty-seven patent family members in twenty-nine countries.
See drug price trends for REZUROCK.
The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this generic product. Additional details are available on the belumosudil mesylate profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2026
Generic Entry Controlled by: Canada Patent 2,608,436
Patent Title: COMPOSES DIARYLHYDANTOINES (DIARYLHYDANTOIN COMPOUNDS)
XTANDI is a drug marketed by Astellas. There are six patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Canada Patent 2,644,530
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Canada Patent 2,648,115
Patent Title: TRAITEMENTS DE L'ALLERGIE OCULAIRE (OCULAR ALLERGY TREATMENTS)
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 06, 2026
Generic Entry Controlled by: Canada Patent 2,604,052
Patent Title: PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DES PATHOLOGIES ASSOCIEES AU SYSTEME NERVEUX CENTRAL (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS)
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can VYVANSE (lisdexamfetamine dimesylate) generic drug versions launch?
Generic name: lisdexamfetamine dimesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 10, 2026
Generic Entry Controlled by: Canada Patent 2,603,873
Patent Title: PROMEDICAMENTS A BASE D'AMPHETAMINE RESISTANTS A LA CONSOMMATION ABUSIVE (ABUSE-RESISTANT AMPHETAMINE PRODRUGS)
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering VYVANSE
See drug price trends for VYVANSE.
The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2026
Generic Entry Controlled by: Canada Patent 2,604,943
Patent Title: SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE
See drug price trends for LO LOESTRIN FE.
The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D'ESTROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE
The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,933
Patent Title: TROUSSE DE STEROIDES, COMPOSITION MOUSSANTE ET UTILISATIONS (STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,207
Patent Title: PREPARATION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can APTIOM (eslicarbazepine acetate) generic drug versions launch?
Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,616,984
Patent Title: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)
This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM
See drug price trends for APTIOM.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,606,258
Patent Title: COMPOSES AZOLE NEUROTHERAPEUTIQUES (NEUROTHERAPEUTIC AZOLE COMPOUNDS)
This drug has twenty-six patent family members in twenty countries. There has been litigation on patents covering XCOPRI
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2026
Generic Entry Controlled by: Canada Patent 2,606,282
Patent Title: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-six patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 04, 2026
Generic Entry Controlled by: Canada Patent 2,649,922
This drug has four hundred and eighty-seven patent family members in forty-five countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2026
Generic Entry Controlled by: Canada Patent 2,609,948
Patent Title: TROUSSE ET COMPOSITION VASOACTIVE ET LEURS UTILISATIONS (VASOACTIVE KIT AND COMPOSITION AND USES THEREOF)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,609,953
Patent Title: COMPOSITIONS EXPANSIBLES SACCHARIDIQUES (SACCHARIDE FOAMABLE COMPOSITIONS)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,610,662
Patent Title: EXCIPIENT EXPANSIBLE ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CELUI-CI (FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2026
Generic Entry Controlled by: Canada Patent 2,606,598
Patent Title: FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC (PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS)
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can TRACLEER (bosentan) generic drug versions launch?
Generic name: bosentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 15, 2026
Generic Entry Controlled by: Canada Patent 2,607,098
Patent Title: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)
TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER
See drug price trends for TRACLEER.
The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2026
Generic Entry Controlled by: Canada Patent 2,606,510
Patent Title: COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
This drug has fifty-eight patent family members in twenty-three countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2026
Generic Entry Controlled by: Canada Patent 2,611,155
Patent Title: FORMULATIONS PHARMACEUTIQUES ET METHODES DE TRAITEMENT UTILISANT CES FORMULATIONS (COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT)
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has twenty-seven patent family members in seventeen countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 05, 2026
Generic Entry Controlled by: Canada Patent 2,609,401
Patent Title: PREPARATIONS DE PEPTIDES AGONISTES DU RECEPTEUR DE L'ERYTHROPOIETINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)
OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can FINACEA (azelaic acid) generic drug versions launch?
Generic name: azelaic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 07, 2026
Generic Entry Controlled by: Canada Patent 2,611,577
Patent Title: KIT ET COMPOSITION ANTIBIOTIQUES ET LEURS UTILISATIONS (ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF)
This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA
See drug price trends for FINACEA .
The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Canada Patent 2,650,263
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2026
Generic Entry Controlled by: Canada Patent 2,655,835
EMBEDA is a drug marketed by Alpharma Pharms. There are nine patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch?
Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2026
Generic Entry Controlled by: Canada Patent 2,550,493
Patent Title: EMBALLAGE DU PYROPHOSPHATE FERRIQUE POUR DIALYSE (PACKAGING OF FERRIC PYROPHOSPHATE FOR DIALYSIS)
TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.
This drug has thirteen patent family members in eleven countries.
See drug price trends for TRIFERIC.
The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.
When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?
Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Canada Patent 2,654,872
This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT
See drug price trends for TEKTURNA HCT.
The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.
When can VAFSEO (vadadustat) generic drug versions launch?
Generic name: vadadustat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 26, 2026
Generic Entry Controlled by: Canada Patent 2,659,682
Patent Title: INHIBITEURS DE LA PROLYL HYDROXYLASE ET PROCEDES D'UTILISATION (PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE)
VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.
This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO
The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,578,626
Patent Title: FORMULATIONS A LIBERATION MODIFIEE D'UN SEL DE BUPROPION (MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT)
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?
Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,654,986
This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering EXFORGE HCT
See drug price trends for EXFORGE HCT.
The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,613,053
Patent Title: FORMES CRISTALLINES DE 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE,ET LEURS PROCEDES DE PREPARATION (CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARBONITRILE ANDMETHODS OF PREPARING THE SAME)
BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318
This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797
This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has four hundred and fifty-nine patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318
This drug has four hundred and fifty-nine patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797
This drug has four hundred and fifty-nine patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318
This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,985,797
This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456
This drug has sixty-eight patent family members in twenty-five countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456
This drug has sixty-eight patent family members in twenty-five countries. There has been litigation on patents covering EPIDUO FORTE
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can RASUVO (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,659,662
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can RASUVO (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,869,671
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: Canada Patent 2,616,580
Patent Title: INHIBITEURS MACROCYCLIQUES DU VIRUS DE L'HEPATITE C (MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS)
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2026
Generic Entry Controlled by: Canada Patent 2,617,681
Patent Title: REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,475
Patent Title: COMPOSITIONS PHARMACEUTIQUES A LIBERATION CONTROLEE DESTINEES A DES MEDICAMENTS ACIDO-LABILES (CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS)
CREON is a drug marketed by
This drug has fifty-one patent family members in fifteen countries.
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,477
Patent Title: NOYAUX CONSTITUES DE MICROGRANULES DE PANCREATINE ADAPTES A UN ENROBAGE ENTERIQUE (PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING)
CREON is a drug marketed by
This drug has fifty-one patent family members in fifteen countries.
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 2,619,591
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 3,050,453
Patent Title: COMPOSES ORGANIQUES FERRIQUES DE QUALITE PHARMACEUTIQUE AINSI QU'UTILISATION DE CEUX-CI ET PROCEDES DE FABRICATION DE CEUX-CI (PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME)
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can BRILINTA (ticagrelor) generic drug versions launch?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: Canada Patent 2,659,328
This drug has one hundred and forty-seven patent family members in forty-four countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can OPSUMIT (macitentan) generic drug versions launch?
Generic name: macitentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Canada Patent 2,659,770
OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT
See drug price trends for OPSUMIT.
The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.
When can OPSYNVI (macitentan; tadalafil) generic drug versions launch?
Generic name: macitentan; tadalafil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Canada Patent 2,659,770
OPSYNVI is a drug marketed by Actelion. There are three patents protecting this drug.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSYNVI
See drug price trends for OPSYNVI.
The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan; tadalafil profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,663,172
Patent Title: PREPARATION MEDICAMENTEUSE EMPECHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,699,142
Patent Title: FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.